Results 241 to 250 of about 790,770 (284)
Selenium‐incorporated polymerized nonfullerene acceptor PCB2Se forms a strong supramolecular complex with SWCNTs, enabling a record‐high zT of 0.29. Sequential N‐DMBI doping, mediated through a polymer‐assisted electron‐transfer pathway, successfully converts the PCB2Se/SWCNT composite into an efficient n‐type material with an impressive power factor ...
Chi‐Chun Tseng +8 more
wiley +1 more source
Molecular remodeling of cancer-associated fibroblasts in breast cancer patients receiving anti-PD-1 immunotherapy. [PDF]
Do KV +5 more
europepmc +1 more source
InSb, a narrow‐bandgap semiconductor with high carrier mobility, is promising for thermoelectric energy conversion but suffers from high lattice thermal conductivity and strong bipolar conduction. Here, in situ interface engineering using Co2O3 nanoprecursors forms hierarchical CoSbx/In2O3/CoSb3 heterostructures that enhance phonon scattering and ...
Jiwu Xin +10 more
wiley +1 more source
Prolonged TNF-α stimulation induces a PD-1-associated exhaustion-like phenotype in mesenchymal stromal cells. [PDF]
Matsunaga N +6 more
europepmc +1 more source
Cyclic Olefin Copolymers as Versatile Materials for Advanced Engineering Applications
Cyclic olefin copolymers (COCs) are presented as highly versatile materials combining tunable synthesis, excellent optical properties, and mechanical robustness. Their potential spans microfluidics, bioengineering, and advanced electronics, while emerging self‐healing and sustainable solutions highlight future opportunities.
Giulia Fredi +3 more
wiley +1 more source
APR-246 drives ROS-dependent ferroptosis and apoptosis and enhances anti-PD-1 efficacy in bladder cancer. [PDF]
Zhang C +8 more
europepmc +1 more source
PD-1 Expression Promotes Immune Evasion in B-ALL. [PDF]
Casado-García A +25 more
europepmc +1 more source
Peripheral blood biomarkers for predicting response to PD-1/PD-L1 inhibitors. [PDF]
Chen S +5 more
europepmc +1 more source
Dual blockades of TIM-3 and PD-1 effectively prevent hyper-progression and enhance the efficacy of anti-PD-1 therapy in high-grade serous ovarian cancer. [PDF]
Li J +9 more
europepmc +1 more source

